Addict Behav Rep. 2017 Sep 23;6:106-111. doi: 10.1016/j.abrep.2017.09.001. eCollection 2017 Dec.
Characteristics of adherence to methadone maintenance treatment over a 15-year period among homeless adults experiencing mental illness.
Addictive behaviors reports
Milad Parpouchi, Akm Moniruzzaman, Stefanie N Rezansoff, Angela Russolillo, Julian M Somers
Affiliations
Affiliations
- Somers Research Group, Faculty of Health Sciences, Simon Fraser University, Blusson Hall, Room 11300 - 8888 University Dr., Burnaby, British Columbia V5A 1S6, Canada.
PMID: 29450244
PMCID: PMC5800549 DOI: 10.1016/j.abrep.2017.09.001
Abstract
BACKGROUND: Methadone maintenance treatment (MMT) has important protective effects related to reduced illicit opioid use, infectious disease transmission, and overdose mortality. Adherence to MMT has not been examined among homeless people. We measured MMT adherence and reported relevant characteristics among homeless adults experiencing mental illness in Vancouver, British Columbia, Canada.
MATERIAL AND METHODS: Homeless adults living with mental illness who had received MMT prior to the baseline interview of the Vancouver At Home study (
RESULTS: Mean MMT MPR was 0.47. A large proportion of participants reported blood-borne infectious disease, three or more chronic physical health conditions, and substance use. Being single and never married was associated with significantly lower MMT MPR (0.40 vs. 0.55,
CONCLUSIONS: The level of adherence to MMT was very low among homeless adults experiencing mental illness. Efforts are needed to improve adherence to MMT as a means of reducing illicit substance use, preventing overdose deaths, and attenuating infectious disease transmission.
Keywords: Adherence; BC, British Columbia; Homeless; MMT, methadone maintenance treatment; MPR, medication possession ratio; MSP, Medical Services Plan; Medication possession ratio; Mental illness; Methadone; Opioid dependence; VAH, Vancouver At Home
References
- J Addict Med. 2017 Jan/Feb;11(1):28-33 - PubMed
- Cochrane Database Syst Rev. 2009 Jul 08;(3):CD002209 - PubMed
- Schizophr Bull. 2017 Jul 1;43(4):852-861 - PubMed
- CMAJ. 2012 Apr 3;184(6):E317-28 - PubMed
- BMJ Open. 2012 Nov 22;2(6):null - PubMed
- JAMA Intern Med. 2013 Feb 11;173(3):189-95 - PubMed
- J Subst Abuse Treat. 2008 Sep;35(2):109-15 - PubMed
- Am J Public Health. 2010 Aug;100(8):1454-61 - PubMed
- J Gen Intern Med. 2007 Jul;22(7):1011-7 - PubMed
- N Engl J Med. 2009 Aug 20;361(8):777-86 - PubMed
- AIDS Behav. 2005 Sep;9(3):251-65 - PubMed
- CMAJ. 2004 Aug 3;171(3):235-9 - PubMed
- Harm Reduct J. 2013 Mar 06;10:3 - PubMed
- Med Care. 1988 Aug;26(8):814-23 - PubMed
- Ther Drug Monit. 2002 Aug;24(4):457-70 - PubMed
- J Addict Dis. 2012;31(3):270-7 - PubMed
- Soc Psychiatry Psychiatr Epidemiol. 2016 Dec;51(12 ):1623-1632 - PubMed
- Trials. 2013 Nov 01;14:365 - PubMed
- Addiction. 2005 Jul;100(7):981-9 - PubMed
- Cochrane Database Syst Rev. 2011 Aug 10;(8):CD004145 - PubMed
- J Addict Dis. 2010 Jan;29(1):1-14 - PubMed
- Curr Pharm Des. 2014;20(25):4097-105 - PubMed
- PLoS One. 2017 Jan 11;12 (1):e0168745 - PubMed
- J Gen Intern Med. 2003 Nov;18(11):921-8 - PubMed
- MMWR Morb Mortal Wkly Rep. 2016 Jan 01;64(50-51):1378-82 - PubMed
- J Addict Med. 2016 Jan-Feb;10 (1):40-5 - PubMed
- BMC Psychiatry. 2015 Feb 26;15:32 - PubMed
- Lancet HIV. 2015 Oct;2(10 ):e445-50 - PubMed
- Drug Alcohol Depend. 2007 Jul 10;89(2-3):306-9 - PubMed
- J Prim Care Community Health. 2015 Jul;6(3):154-61 - PubMed
Publication Types